Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas

The optimal timing for administering high-dose methotrexate (HDMTX) when combined with (R)CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, with/without rituximab) is unclear. Recent data showed that the administration of prophylactic HDMTX before day 10 of R- CHOP may lead to fewer trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Megan, Huang, Ying, Dotson, Emily, Bond, David A., Reneau, John, Epperla, Narendranath, Alinari, Lapo, Brammer, Jonathan, Christian, Beth A., Baiocchi, Robert A., Maddocks, Kami, Sawalha, Yazeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791577/
https://www.ncbi.nlm.nih.gov/pubmed/34788387
http://dx.doi.org/10.1182/bloodadvances.2021005999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791577/
https://www.ncbi.nlm.nih.gov/pubmed/34788387
http://dx.doi.org/10.1182/bloodadvances.2021005999

Ejemplares similares